Abstract
BackgroundT cell responses are at the core of checkpoint inhibitor success in treating cancer; however, generating targeted antigen presentation to stimulate T cell responses remains challenging. Here, we take advantage...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
